EE425 Estimating HCP Labor Time and Cost Saving with the Use of Rapid Rituximab Infusions Versus Standard Rituximab Infusions for the Treatment of Adults with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma in Induction Phase

Intense resource competition for chair time and nursing resources is common in hospitals. This also affects patients undergoing treatment with rituximab standard intravenous infusion (S-IV), which requires ∼240 mins to complete. To address this challenge, this research aimed to quantify the economic and organizational impact of 90-mins rituximab rapid IV infusion (R-IV) in comparison with S-IV on the utilization of healthcare professionals’ (HCP) time for the treatment of adults with follicular ly mphoma (FL) and diffuse large B-cell lymphoma (DLBCL), in the induction phase, in the United Kingdom (UK).
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research